• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, September 6, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Hepatocellular carcinoma: Resection vs. transplantation

Bioengineer by Bioengineer
September 8, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

COLOGNE. Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this option is, however, available to a limited degree only. Curative liver resection is an alternative in this setting. Markus B. Schoenberg, Julian N. Bucher, and coauthors investigated whether liver resection (LR) can yield results that are comparable to those of liver transplantation (LT) (Dtsch Arztebl Int 2017; 114: 519-26).

The authors conducted a meta-analysis of all available studies that compared LT and LR. From the published studies, they analyzed a subgroup consisting of patients with earlier hepatocellular carcinoma (HCC) in compensated cirrhosis, for which LR as well as LT would have been an option. 54 studies including 13 794 patients were included in the subgroup analysis. In this patient population, the researchers compared overall survival after 1, 3, and 5 years, as well as morbidity and mortality in LR and LT.

In patients with early HCC, LT yielded a higher survival rate than LR only after 5 years (66.67% versus 60.35%). After 1 and 3 years the differences did not reach significance. No significant difference in terms of morbidity and mortality was seen in this subgroup.

The researchers concluded that LR in early HCC provides comparably good survival and similar complication rates compared with LT for up to 3 years. Resection should be the objective if the conditions are met. In case of a recurrence, such patients can still be evaluated for transplantation. This strategy could improve the allocation of donor livers. To enable risk stratification, the therapeutic options for the patients should be discussed in a multidisciplinary setting in specialized tumor boards.

###

https://www.aerzteblatt.de/pdf.asp?id=192677

Media Contact

Dr. Markus Rentsch
[email protected]

http://www.aerzteblatt-international.de/int/

http://dx.doi.org/10.3238/arztebl.2017.0519

Share12Tweet8Share2ShareShareShare2

Related Posts

Designing animal research interfaces through a biocentric approach

Designing animal research interfaces through a biocentric approach

September 6, 2026

MCC protein links Wnt signaling to blood vessel polarity and remodeling

September 6, 2026

Isolated CNS familial hemophagocytic lymphohistiocytosis: a diagnostic and treatment case report

September 6, 2026

Targeting MINK1 disrupts glucose metabolism to suppress triple-negative breast cancer

September 6, 2026
Please login to join discussion

POPULAR NEWS

  • Designing animal research interfaces through a biocentric approach

    29 shares
    Share 12 Tweet 7
  • MCC protein links Wnt signaling to blood vessel polarity and remodeling

    29 shares
    Share 12 Tweet 7
  • Isolated CNS familial hemophagocytic lymphohistiocytosis: a diagnostic and treatment case report

    29 shares
    Share 12 Tweet 7
  • Targeting MINK1 disrupts glucose metabolism to suppress triple-negative breast cancer

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Designing animal research interfaces through a biocentric approach

MCC protein links Wnt signaling to blood vessel polarity and remodeling

Isolated CNS familial hemophagocytic lymphohistiocytosis: a diagnostic and treatment case report

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.